An interventional study of Diet Therapy and Calorie Restriction in Obesity, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Obesity by University of Alabama at Birmingham — 13 open to participants now, 17 under way, 1 of them phase 3. Obesity · University of Alabama at Birmingham.
Among the 77 studies in Obesity by University of Alabama at Birmingham, this one is the 59th largest by planned enrollment of the 70 interventional ones that give a count, is one of 5 that started in 2025, is one of 66 with no phase, reaches primary completion later than 4 of the 16 other live ones, and was the 68th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →13 of the 77 studies in Obesity by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Men only
University of Alabama at Birmingham · Sites in United States
Ages 30–79 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2
First in 2000; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 56 across the 70 interventional studies, 360 across the 7 observational. Of the 56 that completed or were terminated, 15 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
6 of the studies in Obesity by University of Alabama at Birmingham that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06989281University of Alabama at BirminghamEvaluation of a Primary Care Based Lifestyle Medicine Clinic at UAB | 2026-12-31 |
| NCT06736028University of Alabama at BirminghamKetogenic Diets for Weight Loss Maintenance: Impact on Energy Expenditure and Appetite in Individuals With Obesity | 2026-12-31 |
| NCT07220213University of Alabama at BirminghamFELLAShip to Better Health | 2027-01-01 |
| NCT05216042University of Alabama at BirminghamGENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study | 2027-04-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 77 studies in Obesity by University of Alabama at Birmingham, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate whether a Ketogenic Diet (KD) can increase Total Energy Expenditure (TEE), while benefiting appetite, during weight loss maintenance in reduced-obese individuals.
The total duration of the intervention will be 10 weeks. Participants will first undergo 4 weeks of a low-energy diet (LED), aiming to induce a minimum of 5% weight loss (weight loss phase). Those who achieve at least a 5% weight loss will then be randomized (1:1) to a 6-week weight loss maintenance (WLM) diet, either a KD or an isocaloric low-fat diet, with the first 2 weeks being a gradual refeeding.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the ketogenic diet will follow a diet with 5% energy from carbohydrates, 70% from fat, and 25% from protein for 6 weeks. The first 2 of the 6 weeks weeks will be a gradual refeeding, with participants slowly withdrawing from the meal replacements used during the 4-week weight loss phase, while introducing more food.
Behavioral: Diet Therapy · Behavioral: Calorie Restriction · Behavioral: Behavioral Support
Participants randomized to the low-fat diet will follow a diet with 50% energy from carbohydrates, 25% energy from fat, and 25% energy from protein for 6 weeks. The first 2 of the 6 weeks weeks will be a gradual refeeding, with participants slowly withdrawing from the meal replacements used during the 4-week weight loss phase, while introducing more food.
Behavioral: Calorie Restriction · Behavioral: Behavioral Support · Behavioral: Diet Therapy
Participants will be provided food to meet the ketogenic diet prescription for the 6-week weight maintenance phase.
Participants will follow a commercial low-energy diet and be provided with meal replacements for 4 weeks aiming to achieve a minimum of 5% weight loss.
Participants will meet weekly with a registered dietitian, for a 20-minute consultation throughout the entire study period (10 weeks) to increase engagement and improve adherence and retention.
Participants will have food provided to meet the standard low-fat diet prescription for the 6-week weight maintenance phase.
Change from baseline total energy expenditure
Total Energy Expenditure (TEE) refers to the total amount of energy (calories) your body uses in a day. Twenty-four-hour EE and RQ will be measured inside the whole room indirect calorimeter (chamber) following standard procedures
Time frame: Baseline, week 6, week 10
Change in appetite ratings
Subjective appetite ratings are personal feelings or perceptions about hunger, fullness, desire to eat (DTE), and prospective food consumption (PFC) usually measured using self-reported scales ranging from "not at all" to "extremely". Subjective appetite ratings (hunger, fullness, DTE and PFC) will be measured using a validated 10cm visual analog scale which will be given to the participants inside the chamber before meals.
Time frame: Baseline, week 6, week 10
Change in total body composition
Bioimpedance analysis (BIA) will be used to measure fat mass, fat-free mass, total, extra, and intra-cellular water.
Time frame: Baseline, week 4, week 6, week 10
Change in total body composition
FM, bone mass, and lean body mass will be determined by dual-energy X-ray absorptiometry (iDXA instrument, GE Healthcare Lunar, Madison, WI) with the use of software version 1.5g (Lunar Corp).
Time frame: Baseline, week 4, week 6, week10
Change in fasting insulin
Circulating (serum) fasting insulin will be measured using validated methods
Time frame: Baseline, week 6, week 10
Change in fasting cholecystokinin
Circulating (plasma) fasting cholecystokinin will be measured by RIA.
Time frame: Baseline, week 6, week 10
Change in fasting ghrelin
Circulating (plasma) fasting ghrelin concentrations will be measured by ELISA
Time frame: Baseline, week 6, week 10
Change in fasting glucagon-like peptide-1
Circulating (plasma) fasting total GLP-1 will be measured by ELISA
Time frame: Baseline, week 6, week 10
Change in fasting peptide YY (PYY)
Circulating (plasma) fasting PYY3-36 concentrations will be measured by ELISA
Time frame: Baseline, week 6, week 10
Change in total body weight
Body weight is the total amount a person weighs when measured on a scale.
Time frame: Baseline, week 4, week 6, week 10
Change in mechanical efficiency
Walking economy will be assessed using a submaximal treadmill test, performed 90 minutes after breakfast. Following a familiarization period, participant will walk on the treadmill at 2 miles/hour for 15 minutes, followed by another 15 minutes at 2.5 miles/hour.
Time frame: Baseline, week 6, week 10
Change in resting energy expenditure
Resting Energy Expenditure (REE) is the amount of energy (calories) your body needs to keep working while you're at rest. Participants will enter the chamber in the morning in the fasting state. REE will be measured while the participant is in the metabolic chamber.
Time frame: Baseline, week 6, week 10
Change in postprandial insulin
Circulating (serum) insulin measured before and 30, 60, 90, and 120 minutes after intake of breakfast with validated methods
Time frame: Baseline, week 6, week 10
Change in postprandial cholecystokinin
Circulating (plasma) cholecystokinin measured before and 30, 60, 90, and 120 minutes after intake of breakfast with RIA.
Time frame: Baseline, week 6, week 10
Change in postprandial ghrelin
Circulating (plasma) ghrelin measured before and 30, 60, 90, and 120 minutes after intake of breakfast with ELISA
Time frame: Baseline, week 6, week 10
Change in postprandial glucagon-like peptide-1
Circulating (plasma) total GLP-1 measured before and 30, 60, 90, and 120 minutes after intake of breakfast by ELISA
Time frame: Baseline, week 6, week 10
Change in postprandial peptide yy
Circulating (plasma) PYY3-36 concentrations measured before and 30, 60, 90, and 120 minutes after intake of breakfast with ELISA
Time frame: Baseline, week 6, week 10
Blood work: beta hydroxybutyrate
Adherence to the dietary interventions will be assessed using objective biochemical analysis through the measurement of beta hydroxybutyrate in blood using a ketone meter.
Time frame: Week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10
Urine sample: acetoacetate
Adherence to the dietary interventions will be assessed using objective biochemical analysis through the measurement of acetoacetate in urine using Ketostix reagent strips.
Time frame: Week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10
Change in glucose
The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating glucose using the SIRRUS analyzer.
Time frame: Baseline, week 6, week 10
Change in total cholesterol
The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating total cholesterol concentrations using the SIRRUS analyzer.
Time frame: Baseline, week 6, week 10
Change in high-density lipoprotein cholesterol
The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating HDL-C using the SIRRUS analyzer.
Time frame: Baseline, week 6, week 10
Change in triglycerides
The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating triglyceride concentrations using the SIRRUS analyzer.
Time frame: Baseline, week 6, week 10
Change in free fatty acids
The fasting blood sample collected before the participants enter the chamber will be analyzed for circulating free fatty acid concentrations using the SIRRUS analyzer.
Time frame: Baseline, week 6, week 10
Change in average appetite
Participants will be asked to report their average hunger, fullness, desire to eat and prospective food consumption (e.g. how hungry did you feel this week? how much did you think about food this week?) over the previous week using a 10-cm visual analogue scale ranging from "not at all" to "extremely".
Time frame: Baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10
Plan to share: Yes — This project will produce demographic information, anthropometric and body composition data, energy expenditure, fat oxidation, plasma concentrations of several gastrointestinal hormones involved in appetite regulation, insulin, glucose, blood lipids, and subjective appetite feelings. Data will be obtained from bioimpedance analysis and dual-energy x-ray absorptiometry (DEXA) for body compsoiiton; ELISA, RIA and other laboratorial methods used for the quantification of hormones and metabolites, and questionnaires and visual analogue scales. Data will be collected from 20 research participants. We estimate to be generating gigabyte (.csv) amounts of data. The methodology, statistical analysis plan, and a data dictionary will also be shared. Based on ethical considerations, scientific data will be de-identified and shared at the participant level. Data will be made available in .csv format and will not require the use of specialized tools to be accessed or manipulated.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: The data will be shared with others by the time the related study is published and will stay available for at least 10 years.
Access criteria: All datasets that can be shared will be deposited in the NIH-supported Vivli repository which specializes in clinical trial data. Given the sensitive nature of the dataset, de-identified human subjects' data will be made available in Vivli, which restricts access to the data to qualified investigators with an appropriate research question who sign a data use agreement.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →